Continuous flow chemistry can transform pharmaceutical manufacturing processes by reducing the number of synthetic steps while increasing yield, enhancing purity and providing more effective quality controls, resulting in reduced capital expenditure and increased speed to market.
Yet the pharmaceutical and biotech industries have yet to fully adopt this transformational technology.
The collaboration between Johnson Matthey (JM) and Snapdragon Chemistry, a leader in flow chemistry process design and technology development, will address this by creating a complete and powerful end-to-end offering that can provide the full scope of process development and manufacturing services, from flow chemistry route conception to cGMP bulk production.
The agreement combines Snapdragon Chemistry's cutting-edge flow chemistry design, development and characterisation capabilities with JM's offering in clinical to commercial API development and manufacturing, which includes considerable quality systems infrastructure, together with JM's expertise in continuous manufacturing processes.
"Snapdragon has outstanding skills, capabilities and people for the development of continuous flow chemistry," commented Robert MacLeod, Chief Executive of JM. "With this collaboration we will be able to unlock significant value for customers through the rapid development of more efficient, sustainable and robust manufacturing processes."
"We are delighted to be partnering with JM," said Matthew Bio, President and CEO Snapdragon Chemistry. "They are a leading provider of API development and manufacturing services and we share similar passions for innovation and delivery of quality science, engineering and materials to our clients."
The two companies have colocated facilities in the Boston area, allowing joint Snapdragon Chemistry and JM teams to interact closely to both develop flow chemistry processes and scale those processes through to manufacturing.
This will allow clients to take full advantage of continuous manufacturing technology throughout the drug development lifecycle.